Skip to main content

Table 1 Comparison of the mean percentage of cells staining positive for MMP9 and PCNA among the treatment groups x ¯ ± SD

From: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer

Group n MMP9   PCNA  
DMSO 10 0.6312 ± 0.1527   0.9156 ± 0.1022  
CoCl2 10 0.6028 ± 0.1337   0.8833 ± 0.1857  
glibenclamide, 10 0.5711 ± 0.1637 F = 324.5 P = 0.00687 0.9017 ± 0.1772 F = 187.6 P = 0.0348
CoCl2 + glibenclamide 10 0.2856 ± 0.1234   0.5289 ± 0.1403  
paclitaxel 10 0.3451 ± 0.1956   0.6574 ± 0.1945